Oramed Pharmaceuticals Reports 2026 Annual Meeting Voting Results

What Happened

• Oramed Pharmaceuticals, Inc. (ORMP) filed an 8-K on Sept. 17, 2026 reporting final voting results from its Sept. 15, 2026 Annual Meeting. Stockholders re-elected the company’s slate of directors, ratified Kesselman & Kesselman (a PwC member) as independent auditors for fiscal 2026, approved an increase to the 2019 Stock Incentive Plan, and approved the company’s executive compensation in a non-binding say-on-pay vote.
• Re-elected directors included Dr. Daniel Aghion, Dr. Miriam Kidron, Nadav Kidron, Dr. Arie Mayer, Yehuda Reznick and Benjamin Shapiro. The board will adopt a three-year frequency for future say-on-pay votes based on the shareholder vote.

Key Details

• Director elections: all listed directors were re-elected; example vote totals — Dr. Daniel Aghion: For 12,662,432 / Against 4,769,203 / Abstain 20,234 (7,538,073 broker non-votes).
• Auditor ratification: Kesselman & Kesselman ratified as independent registered public accounting firm for 2026 — For 22,243,815 / Against 2,717,251 / Abstain 28,876.
• Stock plan increase: Amendment to Amended & Restated 2019 Stock Incentive Plan approved to add 3,000,000 shares, raising the total authorized under the plan to 12,500,000 — For 11,336,951 / Against 6,080,695 / Abstain 34,223 (7,538,073 broker non-votes).
• Say-on-pay and frequency: Non-binding approval of named executive officer compensation — For 13,012,163 / Against 4,394,427 / Abstain 45,279 (7,538,073 broker non-votes). Shareholders selected a three-year frequency: 3 years received 11,377,689 votes (1 year: 5,974,499; 2 years: 13,929; Abstain: 85,752).

Why It Matters

• Board continuity and auditor ratification are governance outcomes that reduce near-term uncertainty about leadership and financial reporting oversight.
• Approval of the stock incentive plan increase authorizes up to 3,000,000 additional shares for equity awards, which can support employee and executive compensation/retention but may lead to future share dilution.
• The say-on-pay approval and selection of a three-year advisory cycle indicate shareholder support for current executive compensation and set the cadence for the next advisory vote on pay.